Stirnimann Guido, Banz Vanessa, Storni Federico, De Gottardi Andrea
Hepatology, Clinic of Visceral Surgery and Medicine, Inselspital, Bern, Switzerland Department of Clinical Research, University of Bern, Switzerland.
Visceral Surgery, Clinic of Visceral Surgery and Medicine, Inselspital, Bern, Switzerland Department of Clinical Research, University of Bern, Switzerland.
Therap Adv Gastroenterol. 2017 Feb;10(2):283-292. doi: 10.1177/1756283X16684688. Epub 2017 Jan 5.
Cirrhotic patients with refractory ascites (RA) can be treated with repeated large volume paracentesis (LVP), with the insertion of a transjugular intrahepatic portosystemic shunt (TIPS) or with liver transplantation. However, side effects and complications of these therapeutic options, as well as organ shortage, warrant the development of novel treatments. The automated low-flow ascites pump (alfapump) is a subcutaneously-implanted novel battery-driven device that pumps ascitic fluid from the peritoneal cavity into the urinary bladder. Ascites can therefore be aspirated in a time- and volume-controlled mode and evacuated by urination. Here we review the currently available data about patient selection, efficacy and safety of the alfapump and provide recommendations for the management of patients treated with this new method.
难治性腹水(RA)的肝硬化患者可采用反复大量腹腔穿刺放液(LVP)、经颈静脉肝内门体分流术(TIPS)或肝移植进行治疗。然而,这些治疗方案的副作用和并发症以及器官短缺,促使人们开发新的治疗方法。自动低流量腹水泵(alfapump)是一种皮下植入的新型电池驱动装置,可将腹水从腹腔泵入膀胱。因此,腹水可以在时间和容量控制的模式下吸出,并通过排尿排出。在此,我们回顾了目前关于alfapump患者选择、疗效和安全性的可用数据,并为采用这种新方法治疗的患者管理提供建议。